Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Top Cited Papers
- 1 August 2002
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 100 (3) , 768-773
- https://doi.org/10.1182/blood-2002-01-0159
Abstract
Ferritin, the iron-storing molecule, is made by the assembly of various proportions of 2 different H and L subunits into a 24-mer protein shell. These heteropolymers have distinct physicochemical properties, owing to the ferroxidase activity of the H subunit, which is necessary for iron uptake by the ferritin molecule, and the ability of the L subunit to facilitate iron core formation inside the protein shell. It has previously been shown that H ferritin is indispensable for normal development, since inactivation of the H ferritin gene by homologous recombination in mice is lethal at an early stage during embryonic development. Here the phenotypic analysis of the mice heterozygous for the H ferritin gene (Fth +/− mice) is reported, and differences in gene regulation between the 2 subunits are shown. The heterozygousFth +/− mice were healthy and fertile and did not present any apparent abnormalities. Although they had iron-overloaded spleens at the adult stage, this is identical to what is observed in normal Fth +/+ mice. However, these heterozygous mice had slightly elevated tissue L ferritin content and 7- to 10-fold more L ferritin in the serum than normal mice, but their serum iron remained unchanged. H ferritin synthesis from the remaining allele was not up-regulated. This probably results from subtle changes in the intracellular labile iron pool, which would stimulate L ferritin but not H ferritin synthesis. These results raise the possibility that reduced H ferritin expression might be responsible for unexplained human cases of hyperferritinemia in the absence of iron overload where the hereditary hyperferritinemia-cataract syndrome has been excluded.Keywords
This publication has 23 references indexed in Scilit:
- Rituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood, 2001
- Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodiesThe Hematology Journal, 2001
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemiaBritish Journal of Haematology, 1997
- Humanized CD52 monoclonal antibody campath‐1H as first‐line treatment in chronic lymphocytic leukaemiaBritish Journal of Haematology, 1996
- Structural motifs involved in human IgG antibody effector functionsEuropean Journal of Immunology, 1993
- Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphomaThe Lancet, 1993
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Reshaping human antibodies for therapyNature, 1988
- Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantationBritish Journal of Haematology, 1986